8-K: Scilex Subsidiary Semnur Amends Denali Merger Agreement to Facilitate Pre-Closing Share Issuance

Scilex Holding Company's subsidiary, Semnur Pharmaceuticals, Inc., has amended its merger agreement with Denali Capital Acquisition Corp. to allow for the issuance of additional shares for potential private placement financing and service provider compensation prior to the business combination.

Summary

• Semnur Pharmaceuticals, Inc., a wholly owned subsidiary of Scilex Holding Company, entered into Amendment No. 2 to its Agreement and Plan of Merger with Denali Capital Acquisition Corp. and Denali Merger Sub Inc. on July 22, 2025.
• The amendment modifies the definitions of 'Exchange Ratio' and 'Merger Consideration' to facilitate the issuance of additional shares of Semnur common stock before the closing of the Business Combination.
• These additional shares are intended for potential private placement financing (referred to as PIPE Shares) and for issuance to advisors and other service providers for services rendered (referred to as Advisor Shares).
• The amendment explicitly maintains the 1.25-to-1 exchange ratio for the Business Combination.
• The Merger Consideration calculation includes a base valuation of $2,500,000,000.00 for Semnur, plus additional consideration for any newly issued shares after the Signing Date and outstanding immediately prior to the Effective Time.
• As of immediately prior to the issuance of Series A Preferred Stock, Semnur will have 785,000,000 authorized shares of capital stock, comprising 740,000,000 authorized Company Common Shares and 45,000,000 authorized Company Preferred Shares.
• Not less than 160,000,000 Company Common Shares will be issued and outstanding immediately prior to the Effective Time, and not more than 6,000,000 shares will be designated and issued as Series A Preferred Stock.

Sentiment

Score: 6

Explanation: The amendment clarifies merger terms and provides crucial flexibility for pre-closing capital raising, which is generally positive for the progression of the Business Combination. However, it also introduces potential dilution for existing shareholders and reiterates the inherent risks associated with complex merger transactions and forward-looking statements.

Positives

• The amendment provides Semnur with increased flexibility to raise additional capital through potential private placement financing prior to the merger's completion.
• It enables Semnur to compensate advisors and service providers with shares, which can help conserve cash resources.
• The explicit maintenance of the 1.25-to-1 exchange ratio offers clarity regarding the share conversion terms for existing shareholders.

Negatives

• The potential issuance of additional shares for financing or compensation could lead to dilution for existing shareholders of Semnur.
• The filing does not specify the exact amount or terms of the potential private placement financing, introducing an element of uncertainty regarding future capital structure.

Risks

• General economic, political, and business conditions could adversely affect the Business Combination.
• There is a risk that the parties may be unable to consummate the Business Combination, or that an event, change, or circumstance could lead to the termination of the Merger Agreement.
• The outcome of any legal proceedings that may be instituted against the parties following the announcement of the Business Combination could be unfavorable.
• The receipt of an unsolicited offer from another party for an alternative business transaction could interfere with the Business Combination.
• Approval from Semnur's stockholders or Denali's shareholders for the potential transaction may not be obtained.
• Failure to realize the anticipated benefits of the Business Combination, potentially due to delays in consummation or difficulties in integrating the businesses of Semnur or Denali, is a risk.
• The Business Combination could disrupt current plans and operations as a result of its announcement and consummation.
• The combined company may face challenges in growing, managing growth profitably, and retaining its key employees.
• A significant amount of redemption requests made by Denali's shareholders could impact the transaction.
• There is a risk of inability to obtain necessary financing for the Business Combination.
• The post-acquisition company may be unable to obtain or maintain the listing of its securities on Nasdaq or OTC Markets following the Business Combination.
• Costs related to the Business Combination could be higher than anticipated.
• Additional unknown or currently immaterial risks could also cause actual results to differ from those contained in the forward-looking statements.

Future Outlook

The Business Combination between Semnur and Denali is proceeding, with the recent amendment providing flexibility for potential future private placement financing and share issuance to advisors. The combined company anticipates future opportunities, though actual events and circumstances are subject to various risks and uncertainties beyond current control, as outlined in the forward-looking statements.

Industry Context

This amendment reflects ongoing strategic consolidation within the biotechnology and pharmaceutical sectors, where mergers and acquisitions are common mechanisms for growth and market expansion. The inclusion of provisions for private placement financing highlights the capital-intensive nature of the industry and the need for flexible funding mechanisms to support development and operational activities.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• The filing mentions the risk of 'the outcome of any legal proceedings that may be instituted against the parties following the announcement of the Business Combination' but does not detail any current or ongoing litigation or regulatory matters.

Stakeholder Impact

• Shareholders of Scilex Holding Company and Denali Capital Acquisition Corp.: The amendment could lead to potential dilution from new share issuances but also offers the prospect of a strengthened financial position for the combined entity. Their approval is a prerequisite for the Business Combination.
• Employees: The Business Combination carries a risk of disrupting current plans and operations, and the ability to retain key employees is identified as a challenge for the combined company.
• Investors and security holders: Advised to thoroughly read the proxy statement/prospectus for comprehensive and important information regarding the Business Combination and its implications.

Next Steps

• Denali Capital Acquisition Corp. will mail a definitive proxy statement/final prospectus and other relevant documents to its shareholders.
• Denali's shareholders will hold an extraordinary general meeting to approve the Business Combination and related matters.
• The Business Combination will proceed, subject to obtaining necessary approvals and financing, and the satisfaction of other closing conditions.

Key Dates

Keywords

Merger Agreement, Business Combination, SEC Filing, 8-K, Scilex Holding Company, Semnur Pharmaceuticals, Denali Capital Acquisition Corp., Private Placement, PIPE Shares, Exchange Ratio, Merger Consideration, Corporate Action, Biotechnology, Pharmaceuticals